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Abstract: Articular cartilage is a unique tissue owing to its ability to withstand repetitive 
compressive stress throughout an individual’s lifetime. However, its major limitation is the 
inability to heal even the most minor injuries. There still remains an inherent lack of 
strategies that stimulate hyaline-like articular cartilage growth with appropriate functional 
properties. Recent scientific advances in tissue engineering have made significant steps 
towards development of constructs for articular cartilage repair. In particular, research has 
shown the potential of biomaterial physico-chemical properties significantly influencing 
the proliferation, differentiation and matrix deposition by progenitor cells. Accordingly, 
this highlights the potential of using such properties to direct the lineage towards which 
such cells follow. Moreover, the use of soluble growth factors to enhance the bioactivity 
and regenerative capacity of biomaterials has recently been adopted by researchers in the 
field of tissue engineering. In addition, gene therapy is a growing area that has found 
noteworthy use in tissue engineering partly due to the potential to overcome some 
drawbacks associated with current growth factor delivery systems. In this context, such 
advanced strategies in biomaterial science, cell-based and growth factor-based therapies 
that have been employed in the restoration and repair of damaged articular cartilage will be 
the focus of this review article. 
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1. Articular Cartilage Structure and Function 
In order to develop biomaterials for articular cartilage repair, it is important to understand the 
structure of the native tissue. Articular cartilage is mainly composed of hyaline cartilage which is 
found on articulating surfaces of bones in diarthroidal joints. It is a specialized connective tissue that 
provides a surface for frictionless movement of opposing bones in the joint. Hyaline cartilage is also 
found on the ventral ends of ribs and is distinguished from the other forms of cartilage by the high 
content of collagen type II and rich proteoglycan matrix synthesized by chondrocytes. This surface acts 
as a shock absorber for the loads experienced due to movement. Together with synovial fluid, this 
tissue provides lubrication and pain free motion with wear resistance over the course of an individual’s 
lifetime [1].  
Articular cartilage forms a thin layer of tissue, varying in thickness depending on the location in the 
body; however, it is fully adapted to withstand compression forces. In humans, the articular cartilage 
can range from 1 to 4 mm depending on the joint [2]. This tissue is able to deform in order to increase 
the total surface area for contact thereby reducing the overall stress. Stress relaxation of articular 
cartilage, indicative of its visco-elastic properties, further demonstrates its unique function in resisting 
damage from applied loads [3]. Furthermore, this tissue is also capable of counteracting compression 
by pressurization of the interstitial fluid with more than 95% of the load carried by fluid [4]. The 
function of articular cartilage in generating resistance against compression and shear forces is 
dependent on the specific arrangement of its extracellular matrix macromolecules. In particular, the 
collagen fiber arrangement and orientation greatly dictate the amount and direction of deformation due 
to applied stress [5].  
Articular cartilage is further organized into four zones: superficial, intermediate (middle), deep and 
calcified cartilage zones (Figure 1). Within the superficial zone, chondrocytes appear flat in shape at 
close proximity to each other and the collagen fibers are aligned parallel to the articular surface. In the 
intermediate zone, chondrocytes are oblique in shape and collagen fibers are randomly organized in 
different directions. Deep zone cartilage however, is characterized by spherical chondrocytes that are 
aligned in columns and the collagen fibers are perpendicular to the articular surface. The collagen 
fibers in the deep zone penetrate through the tidemark into the calcified cartilage to provide structural 
stability for articular cartilage on the subchondral bone [6]. 
2. Articular Cartilage Damage 
Degradation of articular cartilage can arise from trauma, disease or continual mechanical loading. 
There are three main types of cartilage injury: superficial matrix disruption, partial thickness defects 
and full thickness defects. Superficial matrix disruption arises from blunt trauma whereby the ECM is 
damaged but viable chondrocytes aggregate into clusters and are capable of synthesizing new 
matrix [7]. Partial thickness defects disrupt the cartilage surface but do not extend into the subchondral 
bone. These defects are unable to self-repair unlike superficial matrix disruption [8]. Full thickness 
defects arise from damage that penetrates deep into the subchondral bone [1]. These defects can elicit a 
repair response due to access to the marrow cells; however, they are typically filled with fibrocartilage. 
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This type of repair tissue is much weaker than hyaline cartilage and displays poor long-term 
performance due to poor compressive strength and durability and gradually leads to degeneration [9]. 
Traditional cartilage repair techniques attempt to reduce pain as well as restore functionality to 
tissue. The success of these techniques depends on their long-term performance as well as the 
similarity of the repair tissue to native articular cartilage in terms of the composition and mechanical 
properties [6]. Regeneration will not occur without access to cells such as progenitor cells or 
chondrocytes that can undergo chondrogenesis and synthesize de novo tissue. With this in mind, a 
number of repair strategies have been developed. Current clinical treatment techniques include Pridie 
drilling, microfracture, mosaicplasty and autologous chondrocyte implantation (ACI) [9–12]. These 
will be discussed in more detail below. 
Figure 1. The structural organization of articular cartilage from the superficial zone to the 
deep zone and the calcified cartilage. The illustration on the left shows collagen fibers and 
chondrocytes of articular cartilage demonstrating the difference in their orientation and 
shape within the different zones. The histological image (haemotoxylin and eosin (H&E) 
staining) on the right is taken from the femoral condyle of a rabbit knee joint and 
demonstrates the distribution of chondrocytes within the different zones (scale bar 
represents 100 µm). 
 
3. Cartilage Treatment Strategies: Current State of the Art 
In relation to cartilage treatment strategies, Plewes highlighted in 1940 that, “further observations of 
the aetiology and treatment should therefore be of value not only with a view to ascertaining the best 
methods of treatment but also of preventing this crippling condition” [13]. In this regard, articular 
cartilage defects are classified according to their depth and width [14,15]. Healing of defects as a result 
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of mechanical disruption of the chondral tissue limited to the articular surface differs from the healing 
response as a result of mechanical disruption affecting both the articular surface and subchondral bone, 
i.e., an osteochondral defect [16]. Consequently, the choice of a clinical repair technique depends 
largely on the classification of the defects and whether the patient demand requires a palliative, 
reparative or restorative approach. Evidence-based decision algorithms are adopted to determine which 
approach to take depending on factors such as age, lesion size and activity of the patient [17,18].  
3.1. Debridement and Lavage 
Patients with chondral lesions of less than 2 cm2 diameter have been successful candidates for 
primary treatment options such debridement and lavage. This approach involves elimination of loose 
cartilage fragments within the joint. This technique is generally reserved for lower demand older 
patients with limited symptoms who would have difficulty with restricted post-operative 
mobility [19,20]. Although it is considered as a palliative treatment option, relief from pain and 
improvement in quality of life is generally quick with immediate full weight bearing and unrestricted 
activities [19]. 
3.2. Microfracture 
Microfracture is adopted as a secondary treatment option for chondral lesions of less than 2–3 cm2 
in diameter. However, unlike debridement and lavage, microfracture is a reparative strategy and is 
generally reserved for patients with moderate demands [19]. Microfracture involves drilling holes of 
approximately 0.5–1 mm diameter through the articular cartilage tissue and into the bone marrow 
cavity to allow access to bone marrow permitting progenitor cell recruitment to the injured site 
subsequently promoting defect repair [21,22]. However, continuous passive motion with limited 
weight bearing activities post-operatively is required to permit good healing response. Microfracture 
has been widely employed clinically and has been shown to permit effective short term functional 
improvement in joint function [23]. Medium to long term follow up studies have revealed limited 
hyaline-like cartilage tissue formation [24,25] in comparison to other techniques such as autologous 
chondrocyte implantation. Over time, the initially synthesized hyaline-like cartilage becomes more 
fibrous and deteriorates as a result of sub-optimal biomechanical and visco-elastic properties of the 
repair tissue. Inevitably, this repair tissue is prone to failure and a return of symptoms and thus this 
treatment option serves only to delay the eventual requirement for joint replacement [26,27]. A new 
approach is emerging that involves the combination of microfracture and a scaffold in order to enhance 
access to the bone marrow cavity. Erggelet et al. (2009) [28] employed a poly-glycolic acid (PGA) 
scaffold and hyaluronic acid to cover micro-fractured full-thickness articular cartilage defects within a 
sheep model. Compared to the microfracture-only controls which led to fibrocartilage formation, the 
combination of the cell-free scaffolds and microfracture facilitated enhanced cartilaginous repair tissue 
with evidence of collagen type II within the defects. Bone marrow aspirates have widely been used 
clinically for tissue repair. In particular, the use of concentrated bone marrow in combination with a 
scaffold and microfracture has been shown to enhance the regeneration of hyaline-like cartilage 
formation within a defect [29]. 
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3.3. Autografts 
Cell and tissue transplantation are generally reserved for patients with lesions larger than 2 cm2 
diameter as secondary treatment options. These techniques are carried out on intermediate to high 
demand patients following failure as a result of microfracture or debridement to adequately solve the 
underlying problem. Treatment strategies relying on chondral and osteochondral autograft 
transplantation have been employed clinically. Autografts are reserved for small to medium chondral 
and osteochondral defects (up to 3 cm2 diameter) and on high-demand patients of an older age than 
those that would be treated with other procedures. Larger defects can be treated with other procedures. 
Larger defects can be treated using allograft tissue or mosaicplasty whereby a number of cartilage 
tissue plugs are extracted from a non-weight bearing region of the joint and implanted onto the defect 
site [19,30]. Major strengths of graft tissue are that the procedure can be performed arthroscopically as 
well as the fact that the defect is filled with healthy native cartilage. The main limitation of this 
procedure is donor site morbidity, limited lateral integration as well as joint incongruity as a result of 
multiple plugs [19,31].  
4. Advances in Articular Cartilage Repair Using a Tissue Engineering Approach 
The poor long-term outcome of conventional treatment methods used clinically demonstrates that 
there still remains an inherent need for alternative approaches in cartilage defect repair. Tissue 
engineering has shown promise in the repair of defects within cartilage tissue [32,33]. Although the 
rapidly growing field of tissue engineering has received a lot of attention since the late 20th century, 
the process of manipulation of tissue through grafting to restore or repair tissue has been carried out for 
many centuries. More recently, in March 1999, Time Magazine published an article entitled, “How to 
build a body part” by Josh Fishman [34]. It delved into the emerging field of tissue engineering. As the 
author highlights, “yet the era of grow-your-own organs is already upon us, as researchers have 
sidestepped the stem-cell controversy by making clever use of ordinary cells … a teenager born 
without half of his chest wall is growing a new cage of bone and cartilage within his chest cavity”. 
This article received a great deal of attention and the following year a cover story of the May 2000 
issue of Time Magazine included predictions relating to future careers with great promise, listing tissue 
engineering as the top projected career [35]. This brought significant focus to the nascent field and was 
possibly one of the factors which contributed to an increase by international funding bodies of 
investment towards the field of tissue engineering thus resulting in an exponential expansion in 
research in the area from the year 2000 onwards.  
Tissue engineering has been adopted as a means to develop biocompatible substitutes that provide 
the appropriate biological cues to stimulate tissue regeneration with an eventual goal of improving or 
restoring tissue function. It is based on close ties between biomaterial science and cell biology and 
involves the interaction between three key aspects for successful restoration or regeneration of 
damaged tissue. This triad is comprised of cells, scaffolds and biological signal molecules (Figure 2). 
The cell source is fundamental in order to guarantee maintenance of the desired phenotype and 
synthesis of de novo tissue [36]. The scaffolds are required to provide the “template” for the cells to 
lay down synthesized matrix or potentially provide biological cues for modulating cell behavior such 
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as proliferation, migration and differentiation. The biological signaling molecules are required to 
stimulate progenitor cell recruitment, differentiation as well as directing desired tissue synthesis [37]. 
This review will cover these governing areas of tissue engineering and highlight some of the recent 
advances in this rapidly growing field with specific application to cartilage defect repair. 
Figure 2. An illustration of the tissue engineering triad comprised of cells, scaffolds and 
biological signal molecules. (Scaffold scanning electron microscope (SEM) image 
reprinted with permission from [38]. Copyright 2012 Elsevier). 
 
4.1. Cells for Cartilage Defect Repair 
The selection of a suitable cell type is fundamental in tissue engineering (TE) markedly affecting 
the desired repair tissue. A wide range of cell types have been adopted in cartilage TE applications. 
Whilst chondrocytes, the native cell type in cartilage tissue, are an obvious choice of cells, some 
drawbacks associated with their use in vitro have prompted researchers to look for alternative sources. 
Stem cells and progenitor cells derived from a range of sources have been widely investigated and 
show significant promise in cartilage repair. 
4.1.1. Chondrocytes 
Articular cartilage possesses only one cell type; chondrocytes, which are embedded within their 
own rich extracellular matrix. The density of chondrocytes within articular cartilage is approximately 
10,000 cells per mm3, which equates to 1.7% volume of tissue [39]. Taking this into context, it 
suggests that over 98% of articular cartilage is occupied by the extracellular matrix (ECM) which is 
modulated by the single cell type. This highlights the significance of using chondrocytes as viable cell 
sources for defect repair. In vitro studies utilizing chondrocytes have shown the potential of these cells 
in maintaining a chondrogenic phenotype when cultured in three-dimensional environments [40,41]. 
The ability of chondrocytes to synthesize cartilage-like matrix in vitro demonstrates their potential and 
regenerative capacity. Indeed chondrocytes have also been adopted clinically for the repair of chondral 
lesions in autologous chondrocyte implantation. 
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Autologous Chondrocyte Implantation (ACI) 
In ACI, cells are isolated from non-weight bearing regions of a joint such as the lateral trochlear 
ridge [42]. The cells are expanded in vitro and transplanted to a defect and covered with a sutured 
periosteal flap. ACI has been used clinically since 1987 when it was initially introduced by Mats 
Brittberg in Sweden for the management of full thickness chondral defects [11]. A number of studies 
have demonstrated that the repair tissue as result of ACI is more durable and biomechanically similar 
to native hyaline-like cartilage tissue with better long term outcomes than microfracture [11,26,27]. 
The main drawbacks of ACI however, are the two-stage procedure required, the prolonged period of 
time required to expand sufficient numbers of chondrocytes in vitro, and the poor retention and 
dedifferentiation of cells following implantation in the clinic. The requirement of prolonged 
restrictions on weight-bearing through continuous passive motion post-operatively is another major 
drawback of ACI. In addition, a large open arthrotomy is associated with this procedure. Periosteal 
hypertrophy, ablation and loss of implanted cells from the defect site have also been identified as 
limitations of ACI that can lead to the requirement for additional surgery [19,43–45].  
Consensus has yet to be reached on the clinical efficacy of ACI in comparison to microfracture. A 
number of factors come into play in the assessment of clinical outcomes. A study comparing ACI and 
mosaicplasty showed that athletes with chondral defects that were treated with mosaicplasty returned 
to active sports more quickly than those that were treated with ACI. However, the durability and 
clinical improvement was higher with ACI after a 42-month follow-up [46].  
Collagen-Covered Autologous Chondrocyte Implantation (CACI) 
A range of complications are associated with the use of a periosteal flap in ACI procedures, 
including graft delamination, potential ectopic calcification of the periosteal patch, and graft 
hypertrophy which can lead to “catching” of the knee joint. There has thus been a move towards the 
use of an alternative membrane to seal the cartilage defect. A range of different materials have been 
used, however, in the majority of clinical cases collagen-membranes have been used. This procedure is 
termed Collagen-Covered Autologous Chondrocyte Implantation (CACI) or Autologous  
Matrix-induced chondrogenesis or AMIC and marketed as Chondro-Gide® or Bio-Gide® by 
Geistlich Biomaterials (Wolhusen, Switzerland). Gooding et al. (2006) [47] carried out a comparative 
clinical and functional assessment comparing ACI with a periosteal cover (ACI-P) to an ACI with a 
type I/III collagen membrane (ACI-C) in 68 patients. No significant difference was found between 
results at one year post surgery. However, greater than 36.4% of ACI-P grafts showed signs of 
hypertrophy compared to none of the ACI-C grafts. Based on the study outcomes, Gooding 
recommended the use of ACI-C over ACI-P. A range of other clinical studies have also demonstrated 
the effectiveness of this technique [48–52]. 
Matrix-Induced Autologous Chondrocyte Implantation (MACI) 
MACI has been developed as a second generation approach combining chondrocytes and a scaffold 
(matrix) [12,53–56]. The use of a scaffold provides a structure that facilitates chondrocyte adhesion, 
expansion whilst maintaining a chondrocytic phenotype limiting dedifferentiation which has been 
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observed in two-dimensional systems [57]. Indeed, Zheng et al. (2007) [54] found that 75% of biopsies 
from a group of 11 patients at 6 months supported chondrocyte differentiation with resulting  
hyaline-like cartilage formation. A 5 year follow up after treatment with MACI showed that 8 out of 
11 patients rated the function of their treated knees as “much better” or “better” than before 
treatment [10]. Another study carried out a 2–5 year follow-up assessment and showed that the over 
91% of patients developed improved cartilage tissue on treated knees according to the International 
Knee Documentation Committee (IKDC) [58]. Although MACI has shown good healing response with 
better repair than ACI, a major drawback of this approach is the inability to treat large chondral defects 
as well as the inherent donor site morbidity due to chondrocyte harvest from cartilage tissue [59].  
Drawbacks Associated with the Use of Chondrocytes in Cartilage Defect Repair 
Whilst chondrocytes conceivably show great promise in the long term repair of lesions within 
articular cartilage, inherently, they possess some drawbacks that hinder their use in TE. Cell-based 
procedures utilizing chondrocytes, such as ACI, are limited by the size of defects (2–10 cm2 diameter. 
Large defects require more cells; a cell density of 10,000 cells per micro liter (µL) is required in ACI 
and this is limited due to the need for large quantities of autologous tissue harvested from healthy 
regions of joints [19]. The chondrocytes are harvested from cartilage tissue explanted from non-weight 
bearing regions of the joint. The quantity of tissue that can be explanted is limited due to the risk of 
creating secondary critically sized defects as well as donor site morbidity.  
Another drawback associated with the use of chondrocytes is the requirement for monolayer 
expansion prior to implantation in ACI procedures. This expansion period can be detrimental to the 
phenotype of chondrocytes and their capacity to synthesize cartilage-like tissue is diminished as a 
result. Moreover, the lengthy period of expansion is not a financially viable option [60,61]. ACI 
procedures have also been associated with drawbacks such as leakage of chondrocytes from defect 
sites as well as inhomogeneous distribution of cells following injection within the defects [62]. 
Consequently, the use of alternative sources of cells for cartilage defect repair has been widely 
investigated and the following section will explore some potential cell types for this application. 
4.1.2. Mesenchymal Stem Cells 
Adult mesenchymal stem cells (MSCs) have been considered as a promising alternative to 
chondrocytes in the repair of cartilage lesions. This is mainly attributed to their multi-potency (ability 
to differentiate into a variety of connective tissue cells including cartilage-like cells) as well as their 
extensive self-renewal capacity [63]. MSCs also secrete a range of trophic factors such as cytokines 
and growth factors which mediate cellular activity, from differentiation to immunological 
response [64]. It has been shown that MSCs secrete factors that suppress immunological response  
in vitro through inhibition of TNF-α and IFN-γ secretion [65–67]. These cells have an innate capacity 
to inhibit T-cell proliferation in vivo due to their absence of specific surface markers such as CD80 and 
CD86 that inhibit T-cell activity [68]. This characteristic offers great advantages for the use of MSCs 
in regenerative medicine and could have significant impact in progression of future TE 
interventions [69]. MSCs can be derived from a range of sources such as bone marrow, adipose tissue, 
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fat pad as well as synovium tissue. The following section will explore these distinct sources of MSCs 
and their advantages and disadvantages are listed in (Table 1). 
Table 1. Advantages and disadvantages of mesenchymal stem cells (MSCs) from 
various sources. 
MSC type Advantages Disadvantages 
Bone marrow  
stem cells 
[70,71] 
Easily isolated from bone marrow 
High chondrogenic potential 
Broadly characterized and investigated 
Homogeneous population 
Extracting bone marrow is a very painful and 
invasive procedure  
Low yield (approximate 1 in 1 × 105 cells in 
the marrow) 
Decline in proliferative and differentiation 
capacity with age 
Adipose-derived  
stem cells 
[72] 
Abundance of tissue 
High yield (approximate 5000 stem cells 
per gram of aspirate) 
Low donor tissue morbidity 
Inhomogeneous cell population 
Infrapatellar fat  
pad-derived stem 
cells [73] 
High chondrogenic potential 
Low donor site morbidity 
Limited source of tissue 
Synovium-derived  
stem cells [74] 
High yield  
High proliferative rate 
High chondrogenic potential 
Limited source of tissue 
Bone Marrow-Derived Stem Cells 
The bone marrow contains multipotent MSCs that demonstrate a capacity to differentiate into 
different tissue types including cartilage [75]. It is one of the main sources of progenitor cells that are 
used clinically and they have been well characterized and possess surface markers specific to MSCs, 
such as CD44, CD90 and CD105. The MSCs derived from the bone marrow in humans are mainly 
isolated from the iliac crest. The quantity of MSCs in the bone marrow has been shown to decrease 
with age from infancy to adulthood. A newly born child has approximately 1 MSC per 10,000 cells 
whereas a 50 year old adult possesses approximately 1 MSC per 400,000 cells in the marrow [64]. 
Their use in cartilage TE has been extensive both in vitro and in vivo. Examples include bone marrow 
derived MSCs cultured as micromass pellets or on three-dimensional systems which have shown 
potential to differentiate down a chondrocytic lineage [63,76,77].  
Adipose-Derived Stem Cells 
Adipose-derived stem cells (ADSCs) are isolated from lipoaspirates and have been shown to be 
multi-potent with a capacity to differentiation into cartilage-like cells in vitro [78,79]. In addition, 
these cells have been employed in vivo and have the potential to synthesize cartilage matrix 
molecules [80]. A study investigating the characteristics of these cells demonstrated that they possess 
surface markers similar to those of other MSCs. Some of these markers include CD44, CD105 and 
CD166, indicating their true mesenchymal stem-ness [81].  
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Infrapatellar Fat Pad-Derived Stem Cells 
The fat pad in joints has recently been identified as a source of progenitor cells giving a higher yield 
of stem cells without the pain associated with their extraction from tissue, unlike other MSC 
sources [73,82]. These cells have also been shown to display multipotent characteristics with surface 
markers such as CD44, CD90 and CD105 which are indicative of MSCs. As a result, infrapatellar fat 
pad-derived stem cells (IPFSCs) have been recently shown potential in cartilage TE and have shown 
the capacity to produce cartilage-like matrix [83,84]. Thus, this source of cells is a potentially viable 
option for application in cartilage defect repair applications. 
Synovium-Derived Stem Cells 
Synovial tissue has also been identified as a source of progenitor cells with multilineage 
differentiation. The self-renewal capacity of cells derived from the synovium has been shown to be 
phenomenal. Synovial membrane-derived stem cells (SMSCs) have been shown to be capable of 
maintaining a linear growth curve over 30 population doublings [85]. The surface epitopes identified 
on these cells were also similar to other MSCs [86]. SMSCs have been cultured under chondrogenic 
conditions extensively and have shown considerable potential to synthesize cartilage matrix [86,87].  
Comparison of the Chondrogenic Potential of MSCs from Various Sources 
With the increasing numbers of MSC sources available, the question arises: which cell source offers 
the greatest chondrogenic potential? Whilst the ideal cell source has not been identified due to the 
conflicting outcomes of a number of publications, a few noteworthy studies point towards bone 
marrow- and synovium-derived MSCs as being superior to other sources with regards to their 
chondrogenic potential (Table 2). Two studies comparing MSCs derived from synovium, bone 
marrow, periosteum, adipose and muscle tissues demonstrated the superiority of synovium-derived 
MSCs with regards to their proliferative capacity and cartilage matrix deposition [74,80]. Another 
study also showed that bone marrow and synovium-derived MSCs supported significantly higher  
in vivo chondrogenic response than adipose and muscle-derived MSCs [88]. The reason behind the 
superiority of synovium-derived MSCs over other MSCs is not fully understood; however, various 
studies have shown that the healing response of the meniscus and articular cartilage tissue may be 
largely attributed to the synovium tissue [89,90]. Studies have also showed that synovium-derived 
MSCs have an age-independent proliferative and differentiation capacity whereas bone marrow MSCs 
are age-dependent [70,85]. It should also be noted that differences in isolation and culture protocols 
may be the main contributing factor in the differences seen between different studies with regards to 
the response of stem cells from various sources [91]. Moreover, the homologous use of such cells may 
also be a driving factor for their enhanced chondrogenic potential. 
There is growing evidence that there exists a population of progenitor cells that reside within the 
articular cartilage [92]. These cells are known to support appositional cartilage growth from the 
surface. Such chondroprogenitor cells demonstrate a degree of plasticity with potential to form other 
connective tissue types including bone. However, the chondrogenic potential of these articular 
progenitor cells may offer an alternative to the different MSC sources. The main disadvantage of this 
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source of cells however, is the need to extract considerable amounts of articular cartilage to obtain a 
sufficient quantity of cells for expansion and subsequent implantation. 
Table 2. Comparison of the chondrogenic potential of MSCs derived from various 
tissue types. 
Article 
MSC Type Investigated 
Outcome 
Adipose 
Bone 
marrow 
Muscle Synovium Periosteum
Sakaguchi et 
al., 2005 [93] 
√ √ √ √ √ Synovium-derived MSCs displayed 
greater chondrogenic response 
Yoshimura et 
al., 2006 [74] 
√ √ √ √ √ Synovium-derived MSCs displayed 
greater chondrogenic response 
Koga et al., 
2008 [88] 
√ √ √ √ – 
Bone marrow and synovium-derived 
MSCs displayed greater 
chondrogenic response 
Havlas et al., 
2011 [94] 
√ √ – – – No difference between adipose and bone 
marrow MSC chondrogenic response 
Vidal et al., 
2008 [95] 
√ √ – – – Bone marrow-derived MSCs displayed 
greater chondrogenic response 
Reich et al., 
2012 [96] 
√ √ – – – Bone marrow-derived MSCs displayed 
greater chondrogenic response 
4.1.3. Co-Culture Systems 
Co-culture systems are emerging as novel methods to enhance the differentiation and 
chondrogenesis of MSCs. The terminal differentiation, hypertrophy and potential mineralization by 
MSCs in chondrogenic conditions in vitro is a major drawback and may alter the full regenerative 
potential of these cells. This unstable differentiation may progress towards an endochondral 
ossification pathway [97]. As a result, there is a general requirement to maintain the chondrogenic 
differentiated state of MSCs. However, the use of co-culture systems offers a solution to such a 
drawback. There is growing research into the cross-talk between different cell types and how this can 
enhance their regenerative capacity. Chondrocytes have been shown to secrete parathyroid hormone 
related protein (PTHrP) when co-cultured with MSCs subsequently inhibiting the hypertrophy of the 
MSCs [98,99]. Conversely, MSCs have also been shown to enhance the proliferation of chondrocytes 
as well as maintaining their phenotype as a result of synthesis of trophic factors [100]. In addition, 
these co-culture systems have been shown to up regulate chondrocyte related gene expression and 
production of cartilage-like matrix in vitro [101]. Therefore, co-culture systems may overcome some 
of the drawbacks associated with the use of chondrocytes and MSCs independently. One disadvantage 
of these co-culture systems is the complexity of their use as well as the regulatory hurdles which may 
hinder progress in cell-based approaches to cartilage defect repair applications.  
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4.2. Advances in Scaffolds for Cartilage Defect Repair 
A three-dimensional structure is an important characteristic of TE scaffolds as the scaffold acts as a 
template to support interaction, proliferation of cells and deposition of ECM. Moreover, this  
three-dimensional environment should ideally support maintenance of the characteristic cellular 
phenotype and function. Although the composition and surface chemistry of scaffolds plays a 
significant role in the behavior of cells, the structural integrity of the scaffold must also be suitable to 
support the growth of cells. Having the optimal equilibrium between the appropriate composition and 
structural integrity has proven complex. Ideal characteristics of articular cartilage grafts include 
biocompatibility, porous nature to support cell and tissue in-growth, suitable surface chemistry to 
support cell attachment as well as chondro-inductivity [102,103]. Additionally, this ideal biomaterial 
must be able to sustain such characteristics whilst degrading in a manner that does not hinder further 
tissue regeneration [104]. Some of these features will be discussed in more detail below. 
4.2.1. The Effect of Scaffold Composition on Chondrogenesis 
The composition of scaffolds and their associated surface chemistry affects cellular adhesion, 
morphology and subsequently the type of tissue synthesized [105]. Scaffolds can be generally grouped 
into two types; synthetic-based and natural-based. Synthetic scaffolds have the advantage of having 
controllable structural and mechanical properties whereas natural scaffolds have the advantage of 
greater cellular interaction due to the presence of ligands which may facilitate cell adhesion. These two 
scaffold types are presented below highlighting the characteristics that favor their biofunctionality. 
Synthetic Materials Utilized in Cartilage Tissue Engineering 
The most commonly used synthetic materials include polycaprolactone (PCL) poly L-lactic acid 
(PLLA) and polyglycolic acid (PGA) [106–108]. An advantage of synthetic materials is that they are 
pathogen-free and there is low potential for immunological rejection. PCL scaffolds have been used for 
in vitro chondrogenesis with MSCs exhibiting chondrogenic gene expression and matrix 
deposition [76,109]. The controllable degradation rate of polymeric scaffolds has been taken advantage 
of in the development of scaffolds for growth factor delivery [110]. These materials can be fabricated 
into a range of different forms, such as particles, meshes and fibers demonstrating another advantage 
of polymers. However, the main drawback of synthetic materials is that their products of degradation 
are highly concentrated acids and particulates that can result in localized inflammation and cell 
death [111]. Smith and Nephew’s TRUFIT CB® is a licensed and commercially available synthetic  
bi-layered product that is composed of poly-(DL-lactide-co-glycolide or PDLG) as well as calcium 
sulphate for chondral and osteochondral tissue repair applications.  
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Naturally-Derived Materials 
Various natural materials used in TE are derived from components of the extracellular matrix 
(ECM), with polypeptides and polysaccharides being the most widely used due to their 
biodegradability and non-toxic degradation products. Collagen has received the most attention in 
TE [112–114]. This is partly due to its ubiquitous nature as well as its mechanical properties that 
exceed those of other natural materials. Additionally, collagen can easily be tailored to improve its 
mechanical properties and degradation rate, such as through the use of cross-linking treatment [115]. 
Collagen also possesses a number of functional groups along its backbone allowing interaction with 
other molecules, such as polysaccharides and even protein-based growth factors [33]. While Type I 
collagen is traditionally used in collagen-based scaffolds for TE, type II collagen, the principal 
collagen present in articular cartilage, is of particular interest as a material for use in cartilage tissue 
engineering and repair applications. A number of studies have shown the potential of scaffolds and 
gels containing collagen type II to initiate and maintain MSC chondrogenesis [116,117].  
The biofunctionality and regenerative capacity of collagen scaffolds can be significantly improved by 
the addition of GAGs [118]. Indeed, scaffolds fabricated from co-polymers of collagen and GAG have 
been successfully applied in vitro and in vivo for skin, tendon, nerve and conjunctiva [119–121]. In our 
laboratory, chondroitin sulphate has been utilized to fabricate scaffolds for bone repair 
applications [122,123]. Chondroitin sulphate has also been used in cartilage defect repair applications 
in combination with other biomolecules. It has been commonly co-polymerized with collagen and has 
been shown to enhance chondrocyte proliferation and matrix production in vitro [124,125]. Hyaluronic 
acid, a non-sulphated GAG, is a natural material found natively in articular cartilage tissue and is 
synthesized as a long macromolecule with a molecular weight of over 1 MDa but still maintains a high 
level of degradability. Hyaluronic acid is used in the fabrication of a commercially available matrix, 
HYAFF II® (Fidia Advanced Biopolymers, Italy) for osteochondral application. HYAFF II® is a 
derivative of hyaluronic acid formed by esterification of carboxyl groups of the glucuronic acid with 
benzyl alcohol. This material has been shown to support cellular compatibility and enhancement of 
chondrogenesis in vitro by up-regulation of chondrogenic gene expression as well as collagen type II 
and aggrecan deposition [126]. Hyalograft C® was subsequently developed from the HYAFF II® 
scaffold for MACI applications [58,127]. The use of other natural materials such as chitosan, which is 
derived from the shells of crustaceans, for cartilage defect repair application has been realized.  
BST-CarGel which is marketed by Piramal Healthcare is a hydrogel-based material composed of 
chitosan [32]. It is used in combination with bone marrow stimulation and has recently been approved 
for clinical use.  
4.2.2. The Effect of Scaffold Geometry on Chondrogenesis 
The geometry and microarchitecture of scaffolds are key factors that determine adhesion and 
migration of cells as well as the retention of synthesized matrix [109,122,128]. Pore size and porosity 
are important characteristics of scaffolds that can affect cell infiltration and matrix production [129]. It 
is now known that scaffold pores need to be large enough to allow cell migration, where cells 
eventually become bound to ligands presented by the scaffold, but also small enough to establish a 
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sufficiently high specific surface area for cell adhesion [122]. Whilst it is clear that cell adhesion is 
affected by scaffold mean pore size, the behavior of different cell types may be influenced by 
microarchitecture. Cells may require distinct scaffold geometries for adhesion, migration and 
proliferation due to their varying morphologies and sizes, suggesting that from a scaffold development 
perspective, pore size is cell-type specific [130,131]. Therefore, further investigation and 
understanding of mechanisms by which biomaterial architecture affects cell-scaffold interaction and 
subsequent cartilage tissue formation still remains of significant importance. Using a lyophilisation 
process, collagen-based scaffolds can be fabricated in our laboratory with a range of distinct mean pore 
sizes (Figure 3). A previously published study carried out in our laboratory has shown that larger mean 
pore sizes encourage MC3T3 cell (pre-osteoblast-like cell line) attachment, proliferation and 
migration [128]. Furthermore, unpublished work from our group has also shown a similar trend of 
increasing cell attachment and proliferation with increasing mean pore size with a different cell type 
(MSCs). We therefore hypothesize that a scaffold mean pore size range of approximately 300–350 μm 
diameter can support enhanced cell infiltration and matrix deposition. Although both MSCs and 
chondrocytes are much smaller in diameter (approximately 5–15 µm), their attachment and migration 
on scaffolds can be largely affected by the mean pore size. We recently observed encapsulation of cells 
on the periphery of collagen-glycosaminoglycan scaffolds with a mean pore size of less than 100 µm 
whilst scaffolds with mean pore sizes greater than 300 µm encouraged improved cell infiltration 
towards the center. 
Figure 3. Scanning electron microscope images of collagen-glycosaminoglycan scaffolds 
with two distinct mean pore sizes; 94 µm (A); 130 µm (B). The scale bar represents 
100 µm.  
 
4.2.3. The Effect of Scaffold Mechanical Properties on Cell Behavior 
The mechanical properties of scaffolds for cartilage TE play a significant role in the regeneration of 
damaged tissue. Scaffolds must be able to support cell growth and still possess the durability to remain 
uncompromised by the normal functioning of the joint until full regeneration occurs. Articular 
cartilage tissue within joints experiences high compressive stress throughout its normal functioning. 
Therefore, a scaffold designed for cartilage tissue repair must be able to withstand at a minimum, loads 
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applied as part of the tissue regeneration process. On a cellular level, the mechanical properties of 
scaffolds affect the differentiation of MSCs. It is becoming clear that the mechanical properties of a 
substrate greatly affect the lineage that undifferentiated cells follow. Indeed, it has been shown that the 
substrate stiffness can direct MSC differentiation towards specific lineages [132,133]. Engler et al. 
(2006) [132] showed that on gels with low stiffness (0.1–1 kPa), MSCs expressed high levels of 
neurogenic transcriptional factors (NGF, GDNF) as well as neurogenic-specific cytoskeletal factors. 
On gels investigated with intermediate stiffness (11 kPa), MSCs expressed the highest level of 
myogenic transcriptional factors (Pax3, MyoD1). However, on the stiffest gels investigated (34 kPa), 
the seeded MSCs expressed the highest level of osteogenic factors (BMP1, BMP4, CBFα1).  
Murphy et al. (2012) [133] also showed that the scaffolds with the stiffest compressive modulus also 
led to early stage expression of osteogenic markers, whilst the most compliant scaffolds supported 
early stage chondrogenic differentiation in the absence of differentiation factors. Therefore, the use of 
the mechanical properties of scaffolds to direct and enhance the differentiation of MSCs demonstrates 
the importance of such a characteristic in the design and development of advanced tissue engineering 
strategies for cartilage defect repair. 
Studies on stem cell differentiation have traditionally employed growth factors, however, more 
recently a number of studies have demonstrated strong interaction between the mechanical properties 
of substrates (utilizing hydrogels and two-dimensional culture systems) and subsequent cellular 
differentiation. MSCs are capable of demonstrating lineage-specific differentiation when cultured on 
substrates with stiffness that closely matches that of the analogous native tissue [134]. The Young’s 
modulus, often referred to as elasticity or stiffness is an intrinsic ECM characteristic that has 
considerable effect on cell migration, morphology and proliferation [113,135]. The mechanism by 
which cells respond by translating these intrinsic mechanical signals into a cascade of biochemical 
events resulting in gene expression is not fully understood. However, it is becoming more apparent that 
key roles in molecular pathways are played by adhesion complexes and the actin-myosin 
cytoskeleton [136]. 
While the composition of scaffolds is fundamental for cell adhesion through specific ligands on the 
scaffold surface, the scaffold stiffness determines how the cells ‘feel’ their surrounding matrix [133]. 
Cells rely on their substrates by pulling and “feeling” the resistance to deformation which provides 
feedback through mechano-sensitive molecules [137]. These intrinsic mechano-sensitive molecules 
play a significant role in cartilage development and may help guide cells as they mature and assemble 
during repair of damaged tissue. The ideal combination and interplay between these three properties is 
complex, however, an understanding of their role through identification of expression markers is 
imperative and is fundamental in the development of scaffolds for chondrogenesis (Figure 4). 
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Figure 4. An illustration of three scaffold characteristics that have a fundamental role in 
the response of cells. One important property is the microstructure of scaffolds that may 
influence cell infiltration (central scaffold SEM image reprinted with permission  
from [38], copyright (2012) Elsevier). Magnified SEM image shows the microstructure of 
a collagen-based scaffold. The chemical composition is another important property that can 
alter cell-scaffold adhesion. The chemical structure represents a hyaluronic acid 
disaccharide unit, n~5000 (Reprinted with permission from [138], copyright 1972 Nature 
Publishing Group). The mechanical property of the scaffold also plays an important role in 
cell response by influencing cell proliferation, differentiation and migration (the graph 
shows a typical stress-strain curve of a ductile material).  
 
4.3. Biomolecules for Cartilage Defect Repair 
Small chondral lesions have been the target of numerous scaffold-based (biomolecule-free) systems 
developed in TE. However for large defects, localized control over cell and tissue response may be 
required to enhance the healing response. Subsequently, the use of cytokines, hormones and growth 
factors has been adopted in the field of TE to target such large defects. Articular cartilage is inherently 
exposed to a range of biochemical and biophysical stimuli physiologically that affect its homeostasis 
and capacity for regeneration. This section describes some of the key biochemical factors that play a 
significant role in cartilage defect repair. In particular, the use of different biomolecules such as growth 
factor as well as gene therapy approaches which have been used to enhance stem-cell mediated 
chondrogenesis is highlighted in this section. 
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4.3.1. Growth Factors 
Due to the drawbacks associated with the use of chondrocytes such as poor motility and matrix 
deposition, researchers have employed growth factors to overcome such limitations. The potential 
therapeutic application of growth factors has been identified in the field of TE and there is an 
exponential increase in research in this prospective area. Soluble growth factors used for in vitro 
chondrogenesis studies include transforming growth factor beta (TGF-β), basic fibroblast growth 
factor (bFGF) and insulin growth factor (IGF) [139–141]. Bone morphogenetic proteins (BMPs) are 
the most widely available growth factors clinically. BMP-4, -6, and -7 have been shown to promote 
maintenance of a chondrogenic phenotype and up-regulation of cartilage matrix synthesis [97,142]. 
Insulin-like growth factor-1 (IGF-1) is the main anabolic growth factor of articular cartilage and stored 
in the ECM bound to proteoglycans via IGF-1 binding proteins. With increasing catabolic activity, the 
proteolysis of binding proteins also increases and controls the release of IGF-1 [143].  
Fibroblast growth factor (FGF) is a widely investigated growth factor with 22 different forms 
identified so far. Cells expanded in the presence of FGF-2 demonstrate greater chondrogenic capacity 
when transferred to three-dimensional culture [141,144]. The maintenance of a chondrocytic 
phenotype is important for in vitro culture in order to prevent dedifferentiation, common with 
chondrocytes in two-dimensional systems and in addition, to sustain matrix deposition over a 
prolonged period of time. From an in vivo perspective, there are some drawbacks associated with the 
use of bFGF including its non-specificity. In addition, bFGF alone cannot elicit cartilage tissue 
regeneration demonstrating a requirement for a secondary factor to support enhanced chondrogenesis. 
TGF-β is the most commonly used growth factor for in vitro chondrogenesis [63,145]. In particular, 
TGF-β and its isoforms (-1, -2 and -3) have been shown to evoke a chondrogenic response in 
progenitor cells including MSCs. It is a multi-functional growth factor that modulates a range of 
activities, such as control of proliferation and differentiation in addition to maintenance of a 
chondrocytic phenotype of differentiated cells. TGF-β is involved in cartilage homeostasis and is 
secreted in an inactive form bound to a peptide from which it dissociates before becoming active and 
bound to its target receptor. The disadvantages of TGF-β are that it is relatively expensive and the 
potential of chondrocyte hypertrophy through the use of sustained high quantities of such a growth 
factor poses a major problem with regards to subsequent mineral deposition. In this regard, a number 
of studies have shown that a combination of TGF-β with other growth factors leads to greater 
chondrogenic response than TGF-β alone [139,146]. Owing to the chondro-inductivity of TGF-β, the 
potential therapeutic application of this growth factor in cartilage defect repair is a significant area that 
requires investigation. 
Other growth factors that have shown potential for use in cartilage tissue engineering more recently 
include parathyroid hormone related peptide (PTHrP) and platelet-derived growth factor (PDGF). 
PTHrP has been used for MSC and chondrocyte culture, and has exhibited delayed progression 
towards hypertrophy and ossification [147]. Similarly to PTHrP, PDGF has been shown to enhance 
cartilage matrix production by chondrocytes whilst preventing them from advancing towards an 
endochondral maturation pathway through inhibition of alkaline phosphatase activity [148]. PDGF has 
also been shown to up-regulate the proliferative capacity of chondrocytes in vitro [149].  
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A number of commercially available products that are based on growth factors have been approved 
for clinical use demonstrating the promise of such an approach for cartilage defect repair. Stryker’s 
OP-1® and Medtronic’s INFUSE® both for bone tissue application were one of the first growth  
factor-based products available clinically. Their approval demonstrates a significant step for the future 
of this field with regards to regulatory barriers being overcome.  
One major disadvantage of using growth factors for tissue regeneration is the potential for ectopic 
tissue formation in vivo. A classical example is BMP-2, which was approved by the FDA for bone 
tissue regeneration was found to elicit ectopic bone formation. Another disadvantage, the relatively 
short half-lives and short-range diffusion of growth factors suggests that a carrier system is required to 
enhance the action of such proteins for tissue regeneration. Therefore, the control of delivery and 
dosage of growth factors needs to be considered highly prior to their application in vivo. 
4.3.2. The Use of Scaffolds for Delivery of Growth Factors 
The drawbacks associated with a number of growth factor-based products including uncontrolled 
protein delivery demonstrate a requirement for improved carrier systems. High doses of growth factors 
in vivo may be associated with tumorogenesis as well as ectopic tissue formation. Consequently, there 
is an inherent need for optimal delivery systems that ensure targeted spatial-temporal release of the 
therapeutic agent on demand. Scaffolds have the potential to act as carriers for therapeutic agents. The 
successful immobilization of growth factors within scaffolds demonstrates even further the potential of 
using biomaterials to regulate cell behavior and subsequently modulate a repair response. 
A number of studies have taken advantage of the degradation properties of scaffolds to control 
precisely the signaling of growth factors in a local area. The release of the desired growth factor from 
the biomaterial on demand is the main goal of this area in TE. This can be achieved through response 
and interaction of these delivery systems to stimuli such as pH, temperature and enzymatic 
activity [150,151]. A wide range of growth factors have been used within delivery systems and in 
particular, attempts have been made to incorporate TGF-β into biomaterials and scaffolds to improve 
their chondro-inductive nature [145,152].  
The incorporation of growth factors onto scaffolds either chemically through immobilization or 
physically through encapsulation has been widely investigated in TE [150]. This has been achieved 
either through covalent conjugation of the growth factors onto the biomaterial or through secondary 
interactions between the growth factor and the biomaterial. With non-covalent incorporation, the 
absorption of the growth factor exploits direct charge-to-charge interaction with the biomaterial [153]. 
Secondary incorporation may involve the addition of micro-particles that are loaded with the desired 
growth factor, into the biomaterial [154].  
Micro-particles are becoming increasingly used for delivery of growth factors such as TGF-β in 
order to provide greater control over the release kinetics of the growth factor. Micro-particles 
developed from PLGA, chitosan, alginate and gelatin have been widely characterized and have shown 
great potential to control delivery of growth factors [152,155,156]. Within our laboratory, we have 
fabricated micro-particles from a range of materials including alginate as shown in (Figure 5). These 
particles can be used as carriers of growth factors and incorporated within scaffolds to enhance the 
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stability of the biomolecules. A major disadvantage of such micro-particle-based delivery systems is 
the low efficiency of encapsulation of the growth factors.  
Figure 5. Scanning electron microscope image of a collagen scaffold incorporated with 
alginate micro-particles. The micro-particles can be seen adhered to the struts of the 
scaffolds. The scale bar represents a 5 µm length. 
 
4.4. Gene Therapy in Tissue Engineering 
Gene therapy has the potential to overcome the problems associated with localized delivery of 
growth factors. Such problems include the short half-life of growth factors, the potential requirement 
for repeated application as well as poor delivery of the agent resulting in growth factor diffusion away 
from desired area [157]. By using gene transfer to deliver a therapeutic protein to a target cell or tissue, 
the cells essentially act as “factories” that synthesize the protein and induce that cell or tissue to engage 
in repair or regeneration and guide healing. This approach has been proposed to bear great significance 
in the field of cartilage defect repair [158]. Recent advances in this field have led to the use of plasmid 
DNA containing a reporter gene that can stimulate a desired gene expression [159]. More recently, 
scaffolds have been developed and used as carrier systems for plasmid DNA to develop what are now 
termed as “gene activated matrices” (GAMs) [160]. GAMs are biodegradable scaffolds containing 
vectors with genes that can elicit the desired gene expression. Consequently, the GAMs act as delivery 
vehicles for genes whilst also supporting matrix retention [161]. This offers great potential in the field 
of TE especially for cartilage defect repair application. These GAMs have been employed in cartilage 
TE by incorporating plasmid DNA containing reporter genes that can elicit a chondrogenic response of 
seeded cells [162,163].  
The introduction of the desired gene together with the encoding DNA plasmid into the target cell is 
facilitated by either viral or non-viral vectors [164–166]. Whilst viral vectors have been shown to 
promote higher transfection efficiencies, the concerns associated with immunogenicity has warranted 
more emphasis on non-viral vectors. A study using a collagen-glycosaminoglycan (CG) scaffold as a 
carrier for non-viral vectors containing IGF-1 recombinant protein showed that seeded chondrocytes 
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synthesized significantly higher cartilage-like matrix than control scaffolds. Moreover, the release 
kinetics of IGF-1 could be further controlled by the use of cross-linking treatment methods [167]. 
Some elegant studies involving dual axis therapy have showed great potential in cartilage defect 
repair applications [168,169]. These studies used a combination of anabolic (IGF-1) and catabolic  
(IL-1 antagonist) proteins to regulate tissue homeostasis using gene therapy. The catabolic proteins 
inhibit expression of genes related to catabolic tissue response whilst anabolic proteins stimulate 
matrix production. Other studies using gene therapy for cartilage repair applications have utilized 
growth factors such as TGF-β and BMPs [170,171]. 
For a number of years, major concerns have existed about the use of gene therapy in clinical 
applications and major regulatory hurdles exist with their introduction in regenerative medicine. 
However, the approval of the first gene therapy product, Glybera (UniQure) for the treatment of 
lipoprotein lipase deficiency, by the European Union in November 2012 marks a significant milestone 
for the scientific community in general and specifically for the TE field as it opens a gateway for more 
research in this novel area. It provides potential for more funding from grant funding bodies and 
venture capitalists to be directed towards these areas and optimism for researchers to see their work 
proceed from bench-top towards commercialization. 
5. Concluding Remarks 
Tissue engineering (TE) has witnessed significant advances as a result of the collaboration between 
researchers from cell biology, biomaterial science and engineering. The latest research in the field of 
cartilage TE suggests a shift away from the use of chondrocytes to multipotent mesenchymal stem 
cells (MSCs). The identification of MSCs within different sources such as synovial and adipose tissue 
has offered a solution to the drawbacks associated with the use of chondrocytes. In addition, their 
immunosuppressive characteristics offer great benefits for researchers carrying out in vivo studies. The 
ever growing use of biomimetic approaches in designing biomaterials for cartilage defect repair 
demonstrates significant advances in this field. Moreover, the incorporation of recombinant growth 
factors to further improve the chondro-inductivity and subsequent regenerative capacity of scaffolds 
may play a major role in development of constructs for large chondral defects. The emergence of gene 
therapy in TE which has been identified to offer superior localized control over cell and tissue 
response demonstrates significant promise in the development of advanced TE strategies for cartilage 
defect repair. Accordingly, such progress demonstrates affirmative prospects for the field of TE and 
offers a promising alternative to the current solutions to the problem of articular cartilage defect repair. 
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